Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prolyl Hydroxylase EGLN2 (PHD1)
- Target
- PHD1
- Molecular classification
- Enzyme, Fe(II)-dependent dioxygenase
01
Overview
Prolyl hydroxylase EGLN2 (PHD1) is an oxygen-sensing enzyme that hydroxylates proline residues on hypoxia-inducible factor alpha (HIFα) proteins under normoxic conditions, targeting them for proteasomal degradation. Under hypoxia, EGLN2 activity is reduced, leading to HIFα accumulation and activation of the hypoxic response. It plays roles in apoptosis, cell cycle regulation, mitochondrial function, and various diseases including cancer and ischemia. Its inhibition is explored as a therapeutic strategy, but requires careful consideration due to its dual roles and potential off-target effects.
- Other names
- Egl-9 family hypoxia inducible factor 2HIF-PH1EIT6
02
Mechanism of action
Inhibition of prolyl hydroxylation of HIFalpha, leading to increased HIFalpha stability and transcriptional activity.
03
Biological functions
Oxygen sensingHypoxia responseRegulation of apoptosisCell cycle regulationMitochondrial functionRegulation of HIFalpha
04
Disease associations
CancerIschemia/reperfusion injuryNeurodegenerative disease
05
Safety considerations
Potential for context-dependent effects (tumor-suppressive vs. tumor-promoting)Off-target effects on other proline hydroxylation targets
Beyond the preview
Go deeper on Prolyl Hydroxylase EGLN2 (PHD1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prolyl Hydroxylase EGLN2 (PHD1).